NCT00074529已完成2 期
A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of MK-0677 25 mg in Slowing the Progression of Alzheimer's Disease
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 512
- 主要终点
- Cognitive function over 12 month period; safety and tolerability
研究概览
简要总结
An investigational drug (MK0677) will be studied to determine whether it helps the memory and cognition of patients with Alzheimer's Disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Cognitive function over 12 month period; safety and tolerability
时间窗: over 12 month period
次要结局
- AD symptoms over a 6 month and 12 month period measured by the CIBIC + and the ADAS-Cog.(over a 6 month and 12 month period)
研究者
相似试验
已完成
2 期
Investigation of Memantine in the Treatment of Memory, Concentration or Attention ProblemsMemory DisorderRetention Disorder, CognitiveSubjective Cognitive ImpairmentMemory, Concentration or Attention ProblemsNCT01261741Merz Pharmaceuticals GmbH299
已完成
2 期
SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD)Alzheimer's DiseaseNCT00093951Saegis Pharmaceuticals280
已完成
2 期
Trial of Memantine for Cognitive Impairment in Multiple SclerosisCognition DisordersMultiple SclerosisNCT00300716Oregon Health and Science University82
已完成
2 期
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.Alzheimers DiseaseDementiaAlzheimers Disease, FamilialNCT04623242Washington University School of Medicine194
已完成
2 期
Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's DiseaseCentral Nervous System DiseasesCognitionAlzheimer's DiseaseNCT01073228FORUM Pharmaceuticals Inc409